- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Vor Biopharma Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Mo | Vor Bio appoints two industry veterans to its board of directors | 1 | Investing.com | ||
| Mo | Vor Biopharma: Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 18.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 154 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| 17.07. | Vor Biopharma: Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer | 134 | GlobeNewswire (Europe) | Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience... ► Artikel lesen | |
| 10.07. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.07. | Vor Bio beruft Branchenveteran Sandy Mahatme zum Finanz- und Geschäftsvorstand | 2 | Investing.com Deutsch | ||
| 10.07. | Vor Bio appoints Sandy Mahatme as CFO and CBO | 1 | Investing.com | ||
| 10.07. | Vor Bio appoints Sandy Mahatme as CFO | 1 | Seeking Alpha | ||
| 10.07. | Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer | 683 | GlobeNewswire (Europe) | Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass.,... ► Artikel lesen | |
| 01.07. | Vor Biopharma: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 167 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| 30.06. | Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market | 3 | Benzinga.com | ||
| 30.06. | Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal | 4 | Investing.com | ||
| 30.06. | Vor Biopharma: H.C. Wainwright stuft Aktie nach Telitacicept-Deal auf "Kaufen" hoch | 9 | Investing.com Deutsch | ||
| 26.06. | Vor Biopharma Stock Soars 73% On $175 Mln Private Placement Deal | 3 | RTTNews | ||
| 26.06. | Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding | 2 | MedCity News | ||
| 26.06. | Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions | 2 | FiercePharma | ||
| 26.06. | Vor Bio surges after private placement, licensing deal | 2 | Seeking Alpha | ||
| 26.06. | Vor Biopharma stock soars after licensing deal for autoimmune therapy | 4 | Investing.com | ||
| 26.06. | Stifel maintains hold rating on Vor Biopharma stock amid strategic shift | 1 | Investing.com |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENCELL BIOSCIENCE | 15,040 | -0,92 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| PROKIDNEY | 3,275 | +0,46 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen | |
| ATHIRA PHARMA | 0,462 | -0,24 % | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen | |
| EVOTEC | 7,252 | +6,46 % | Evotec Aktie stürzt trotz bestätigter Ergebnisprognose ab: Basisgeschäft schwierig | Aktuelle Nachrichten lassen die Evotec heute deutlich fallen: Das Hamburger Biotech-Unternehmen hat seine Umsatzprognose für das laufende Jahr gesenkt. Statt 840 bis 880 Millionen Euro erwartet das... ► Artikel lesen | |
| QIAGEN | 43,870 | +0,52 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,230 | +9,09 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping | -- On track for planned BLA submission for del-zota at year end 2025 --
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,490 | +3,67 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| ARCELLX | 71,31 | +1,48 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 40,820 | -1,97 % | Apogee Therapeutics und der 50-Milliarden-Dollar-Markt | Anfang der Woche hatten wir erstmals über Apogee Therapeutics und dessen jüngste Studienergebnisse berichtet. Weiterhin ergibt sich bei der Aktie eine hochattraktive Gelegenheit, die kurzfristige Kursschwäche... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,070 | -0,98 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| BIONTECH | 98,15 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2025 Ergebnisse für das zweite Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 4. August 2025, die Ergebnisse für das zweite Quartal 2025 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
| IMMUNOVANT | 16,930 | -7,59 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| ABSCI | 2,885 | -17,81 % | Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics | ||
| SUMMIT THERAPEUTICS | 28,680 | +4,03 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| NUVALENT | 81,47 | -0,74 % | Nuvalent, Inc.: Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC | CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,46 % bei einem Aktienkurs von 2,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.